LORATI Successfully Develops Effective Treatment for AIDS

A powerful breakthrough drug has been successfully developed targeting the 35+ million people living with HIV/AIDS globally

Jul 14, 2015, 09:15 ET from Lorati Company Ltd.

TAIPEI, July 14, 2015 /PRNewswire/ -- Lorati Company Limited, a Taiwan-based biotechnology and skincare company, today announced that it has successfully developed nano-medication, which can effectively inhibit HIV-1 viral replication.

Lorati CEO, David Lo, said nano-medication, based on bentonite, also known as God's dirt, is believed to be the last-ditch treatment for AIDS. Unbelievable improvement can be obtained within one month of treatment by nano-medication. After being treated for a couple of months, AIDS patients can even go back to HIV-1 status, meaning the number of CD4+ cells increases substantially.

According to a test report from The Johns Hopkins University School of Medicine, nano-medication can 100% inhibit replication of HIV-1 in vitro. "No existing drug and/or regiment of drugs for HIV-1/AIDS can achieve the same performance," said Mr. Lo.

Furthermore, it has been scientifically verified that nano-medication does not cause any side effects. Neither does it have any drug resistance issues. "If AIDS patients want to be out of a critical condition, nano-medication is the only resort," said Mr. Lo.

Mr. Lo explained, "Nano-medication can tackle HIV-1 both extracellularly and intracellularly. Nano-particles of nano-medication can bond to HIV-1 spikes, which are polar chemicals and consist of glycoprotein 120 (gp120) and glycoprotein 41 (gp41). Since gp120 contains 50% of glycans, it is extremely difficult for organic medicine to bond to it."

Bonding between gp120/gp41 and human cell receptors is achieved through van der Waals force or static force. However, the bond between nano-particles and gp120/gp41 is ionic. With stronger force in ionic bonding, nano-medication will prevent HIV-1 from attaching to human cell receptors. As a result, CD4+, CCR5, CXCR4, and HIV-1 can't infect human cells and reproduce its progeny, which will kill HIV-1 extracellularly.

Mr. Lo further explained, nano-particles of nano-medication, through caveolae, can enter the cytosol. These nano-particles will then bond to the enzymes required for HIV-1 replication. They will function like various inhibitors to invalidate enzymes required for HIV-1 replication, such as PI (protease inhibitor) and NNRTI (non-nucleoside reverse transcriptase inhibitors). Through this process, nano-particles will stop HIV-1 from replicating.

In addition, when nano-particles meet with HIV-1 (HIV-1 spikes and enzymes), it is a physical reaction. Based on this fact, nano-medication will not cause mutations in HIV-1.

Delirium is the most common cognitive disorder in hospitalized patients with AIDS. Usually, one year prior to AIDS patients passing away, HIV-1 will attack the brain which explains the cause of the cognitive disorder. "No existing drug or medication in the world can tackle HIV-1 in the brain due to the blood-brain-barrier (BBB). Thus far, only nano-medication can overcome BBB as evidenced by successful treatment of brain cancer," said Mr. Lo. "Nano-medication, in some way, certifies the statement, God formed man out of dirt from the ground."

The company is now looking for strategic partners to conduct clinical trials on AIDS, and is open for discussion with regard to any forms of collaboration.

Contact: 

Lorati Company Ltd.
Mr. David Lo
Tel: +886 912 549 632 / +886 4 2483 0545
Email: david@lorati.com.tw  
Website: www.lorati.com.tw

SOURCE Lorati Company Ltd.